Structure-Guided Design of G-Protein-Coupled Receptor Polypharmacology.
Parkinson's disease
drug design
polypharmacology
receptors
virtual screening
Journal
Angewandte Chemie (International ed. in English)
ISSN: 1521-3773
Titre abrégé: Angew Chem Int Ed Engl
Pays: Germany
ID NLM: 0370543
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
30
01
2021
pubmed:
28
4
2021
medline:
3
11
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
Many diseases are polygenic and can only be treated efficiently with drugs that modulate multiple targets. However, rational design of compounds with multi-target profiles is rarely pursued because it is considered too difficult, in particular if the drug must enter the central nervous system. Here, a structure-based strategy to identify dual-target ligands of G-protein-coupled receptors is presented. We use this approach to design compounds that both antagonize the A
Identifiants
pubmed: 33904641
doi: 10.1002/anie.202101478
pmc: PMC8456950
doi:
Substances chimiques
Antiparkinson Agents
0
DRD2 protein, human
0
Ligands
0
Receptor, Adenosine A2A
0
Receptors, Dopamine D2
0
Small Molecule Libraries
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18022-18030Informations de copyright
© 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.
Références
J Neurosci. 2001 May 15;21(10):RC143
pubmed: 11319241
Nat Rev Drug Discov. 2004 Feb;3(2):136-51
pubmed: 15040578
J Med Chem. 2016 Jul 14;59(13):6470-9
pubmed: 27312113
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
Eur J Pharmacol. 1987 Sep 2;141(1):101-7
pubmed: 3117576
J Med Chem. 2009 Sep 24;52(18):5590-602
pubmed: 19711895
Angew Chem Int Ed Engl. 2021 Aug 9;60(33):18022-18030
pubmed: 33904641
Nature. 2012 Dec 13;492(7428):215-20
pubmed: 23235874
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954
pubmed: 27899562
J Med Chem. 2014 Oct 9;57(19):7874-87
pubmed: 24946140
Lancet. 2009 Jun 13;373(9680):2055-66
pubmed: 19524782
Drug Discov Today. 2004 Aug 1;9(15):641-51
pubmed: 15279847
J Neurosci. 2006 Dec 27;26(52):13548-55
pubmed: 17192438
Curr Opin Struct Biol. 2006 Feb;16(1):127-36
pubmed: 16442279
Nature. 2009 Nov 12;462(7270):175-81
pubmed: 19881490
Ann Neurol. 2012 Feb;71(2):278-82
pubmed: 22367999
Eur J Med Chem. 2001 Sep;36(9):719-30
pubmed: 11672881
Science. 2011 Apr 15;332(6027):322-7
pubmed: 21393508
Nature. 2020 Aug;584(7819):125-129
pubmed: 32528175
Nat Commun. 2016 Jul 26;7:12298
pubmed: 27457610
Pharmacol Ther. 2011 Dec;132(3):280-99
pubmed: 21810444
J Med Chem. 2019 Apr 25;62(8):3784-3839
pubmed: 30351004
ACS Chem Neurosci. 2011 Jun 15;2(6):308-16
pubmed: 22778874
Nat Rev Cancer. 2010 Feb;10(2):130-7
pubmed: 20094047
J Chem Inf Model. 2010 Sep 27;50(9):1561-73
pubmed: 20735049
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
Nat Rev Drug Discov. 2018 Nov;17(11):804-822
pubmed: 30262889
Nat Struct Mol Biol. 2019 Jul;26(7):535-544
pubmed: 31270468
J Med Chem. 2006 Dec 28;49(26):7559-83
pubmed: 17181137
Nature. 2018 Mar 8;555(7695):269-273
pubmed: 29466326
J Med Chem. 2013 Nov 27;56(22):8955-71
pubmed: 23919353
Annu Rev Pharmacol Toxicol. 2012;52:153-78
pubmed: 21910627
Nat Rev Drug Discov. 2004 Apr;3(4):353-9
pubmed: 15060530
Trends Pharmacol Sci. 2018 May;39(5):494-512
pubmed: 29576399
J Med Chem. 2012 Jun 14;55(11):5311-25
pubmed: 22563707
J Med Chem. 2015 Feb 12;58(3):1550-5
pubmed: 25590655
Lancet Neurol. 2014 Aug;13(8):767-76
pubmed: 25008546
J Med Chem. 2008 Feb 14;51(3):347-72
pubmed: 18181565
J Chem Inf Model. 2015 Nov 23;55(11):2324-37
pubmed: 26479676
Trends Pharmacol Sci. 2013 Jan;34(1):59-66
pubmed: 23177916
J Med Chem. 2020 Mar 12;63(5):1779-1797
pubmed: 31499001
Front Pharmacol. 2017 Dec 14;8:898
pubmed: 29311917
Structure. 2011 Sep 7;19(9):1283-93
pubmed: 21885291
Nat Chem Biol. 2017 Nov;13(11):1143-1151
pubmed: 29045379
Sci Rep. 2018 Jan 8;8(1):41
pubmed: 29311713
Nat Rev Drug Discov. 2011 May;10(5):377-93
pubmed: 21532567